Skip to main content
MyDeficiencies

Follitropin alfa

Gonadotropin (recombinant FSH)

Also sold as Gonal-f, Gonal-f RFF.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Follitropin alfa (Gonal-f) is a recombinant glycoprotein hormone given by subcutaneous injection. Its own FDA labeling states its metabolism "has not been studied in humans," it induces or inhibits no cytochrome P450 enzyme, and the label reports no evaluated drug-interaction potential at all. Because it is not absorbed through the gut, not hepatically processed like a small molecule, and cleared renally as a protein rather than excreted unchanged, none of the classical absorption-interference, enzyme-induction, or cofactor-antagonism mechanisms that drive most drug-nutrient depletions apply here. That absence is itself the headline: this is not a drug with a hidden micronutrient-depletion profile waiting to be documented, and this review found no credible, drug-specific classical-nutrient claim circulating for it either.

Gonadotropin (recombinant FSH) · ATC G03GA05 · also sold as Gonal-f and Gonal-f RFF · reviewed 2026-09-26. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Follitropin alfa in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Sodium - dilutional hyponatremia, bounded to OHSS

Orange — Moderate

See study details

In moderate-to-severe OHSS, a labeled complication of follitropin alfa therapy, capillary-permeability-driven fluid shifts produce dilutional hyponatremia. This is a disturbance of sodium handling during the complication, not a dietary sodium deficiency.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Negative/null findings: No significant blood-volume or osmolality change occurred in uncomplicated stimulation cycles without OHSS in the hemoconcentration study used for the oxygen-delivery entry below [5].
  • At-risk subgroups: Patients who develop moderate/severe OHSS; the label associates OHSS risk with "previous or current ovarian cyst and polycystic ovaries" [1]. Pregnancy (conceptual cycles) prolongs the derangement per plasma-renin data in a related gonadotropin [4].

Regulatory status

FDA labeling lists "electrolyte imbalances" among the clinical findings of OHSS and directs assessment of "fluid intake and output... serum and urinary electrolytes, urine specific gravity" during OHSS management. [1]

Population evidence

Case literature reports serum sodium 127 mmol/L (reference 135-145) in a patient with OHSS after IVF-embryo transfer, with hyponatremia described as occurring in "more than 50%" of OHSS presentations in the cited literature [6]. That case report's cohort did not name the specific FSH product used - class-level for the quantitative prevalence figure. The drug-specific evidence is the label's own listing of electrolyte imbalance as an observed OHSS finding for this product [1].

Mechanism

Named: VEGF-driven increase in capillary permeability causes third-spacing of intravascular fluid into the peritoneal/pleural space, hypovolemia, and a resetting of the osmotic threshold for arginine-vasopressin (ADH) release, producing dilutional (not depletional) hyponatremia.

Counter-evidence held on record

No electrolyte disturbance is expected or reported in stimulation cycles that do not progress to at least moderate OHSS. This is a dilutional/hormonal disturbance, not a dietary sodium deficiency (Hard Rule 5). It must never be presented as a reason to increase sodium intake - fluid restriction and clinical monitoring, not sodium supplementation, is the actual management, and it is a prescriber-managed complication, not a self-directed nutrition fix.

Potassium - hyperkalemia risk, bounded to OHSS

Orange — Moderate

See study details

The Gonal-f label specifically instructs ECG monitoring for hyperkalemia as part of OHSS management - a labeled risk of potassium excess/retention in this bounded subgroup, not a depletion.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Negative/null findings: The renin/aldosterone study did not report electrolyte values in the accessible record [4].
  • At-risk subgroups: Same OHSS-prone subgroup as the sodium entry; pre-existing renal impairment would compound hyperkalemia risk.

Regulatory status

FDA label instructs clinicians managing OHSS to obtain an "electrocardiogram to monitor for hyperkalemia" alongside BUN/creatinine, total proteins/albumin ratio, and coagulation studies. [1]

Population evidence

A directly quantified potassium value in a follitropin-alfa-specific cohort was not located during this review; the labeled monitoring instruction itself is the primary drug-specific evidence (Tier A, this product's own label).

Mechanism

Partially named, and contested in direction: severe OHSS causes renal hypoperfusion from hypovolemia/hemoconcentration, which can impair potassium excretion (retention risk). A separate line of evidence documents secondary renin-angiotensin-aldosterone activation in OHSS, with plasma renin activity rising from a control mean of 3.0 ng AI/mL/hr to 55.0 ng AI/mL/hr (range 29-95) in severe OHSS (P<0.001) [4] - aldosterone activation would ordinarily promote renal potassium wasting, the opposite direction. That study used menotropin, not follitropin alfa (class-level, excluded-cohort for this specific drug).

Counter-evidence held on record

The direction of potassium change in OHSS is not fully resolved by the sources reviewed here - competing renal-hypoperfusion (retention) and aldosterone-mediated (wasting) mechanisms point opposite ways, which is precisely why the label calls for direct ECG/lab monitoring rather than presuming one direction. This is a labeled risk of potassium derangement during a drug complication, not a nutritional potassium deficiency. Never recommend potassium supplementation on the basis of this entry; the hazard, if anything, runs toward excess.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden - localized ovarian increase

Yellow — Low

See study details

In human granulosa cells exposed to Gonal-f (follitropin alfa) directly, FSH increases mitochondrial basal respiration in a concentration-dependent manner - a localized, intended ovarian effect, not evidence of systemic mitochondrial harm.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Negative/null findings: Effect was concentration-dependent and most pronounced at the supraphysiological (600 mIU/mL, roughly 100x physiologic) exposure; physiologic-range exposure produced smaller effects on some endpoints [7].
  • At-risk subgroups: None identified; this is a localized ovarian/follicular finding, not a patient-wide effect.

Regulatory status

Not addressed in FDA labeling.

Population evidence

In vitro study of cumulus and mural granulosa cells from 38 women (age 20-35) undergoing ICSI at a Dutch reproductive center, exposed to recombinant FSH from a GONAL-f pre-filled pen at 6, 60, and 600 mIU/mL. Mitochondrial basal respiration increased significantly with supraphysiological FSH (P<0.01 in cumulus cells, P<0.05 in mural cells) [7]. Tier B: mechanistic, human cells, this drug used directly.

Mechanism

Named: FSH-receptor signaling drives mitochondrial biogenesis/respiratory upregulation in granulosa cells to support oocyte maturation and steroidogenesis.

Counter-evidence held on record

No source reviewed shows FSH suppressing or damaging granulosa mitochondria at clinically used concentrations. This is an increase, not a burden, and is confined to stimulated ovarian tissue. It must never be marketed as a systemic mitochondrial-support benefit for the patient, nor as evidence that follitropin alfa depletes mitochondrial nutrients (see Fails verification).

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress - transient, localized, negligible damage

Yellow — Low

See study details

FSH exposure triggers measurable free-radical generation inside human granulosa cells within two hours, concentrated in the mitochondria, but produces negligible oxidative damage to DNA, protein, or lipids except lipid peroxidation at the highest, supraphysiologic concentration tested alone.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Negative/null findings: The authors' own conclusion is a direct null finding on damage: "the elevated free radical load causes neglectable oxidative damage in both cGCs and mGCs" [7].
  • At-risk subgroups: None identified beyond the localized follicular compartment.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Same in vitro study as above [7]: FSH induced statistically significant free-radical generation across all tested concentrations (P<0.01 after 2 hours) via fluorescent-nanodiamond relaxometry and DCFH-DA assay; "no oxidative damage to GC DNA/RNA, proteins, or lipids was found upon FSH exposure at any concentration except elevated lipid peroxidation in the FSH group of 600 mIU/mL (P<0.05)." Tier B, this drug used directly.

Mechanism

Named: receptor-mediated free-radical signaling as part of normal follicular/oocyte maturation signaling, with cellular antioxidant capacity sufficient to prevent measurable damage except at the highest, non-physiologic concentration tested.

Counter-evidence held on record

The study's own negative-damage finding is itself the counter-evidence to a general "FSH causes oxidative damage" claim. Transient, low-magnitude, localized signaling in the stimulated ovary - not a systemic oxidative-stress burden, and not by itself an indication for antioxidant supplementation.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper - estrogen/ceruloplasmin class extrapolation

Yellow — Low

See study details

Follitropin alfa drives supraphysiologic estradiol production; estrogen is an established, class-level (non-FSH-specific) inducer of hepatic ceruloplasmin synthesis and secondary serum copper elevation, but no follitropin-alfa-specific measurement of this effect was located.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Negative/null findings: A prospective IVF trace-element pilot study (n=51, ICSI/PGT-A/frozen embryo transfer) measured copper alongside seven other trace elements in urine, follicular fluid, and blood, but only correlated baseline/peri-retrieval levels with implantation and live-birth odds - it was not designed to test, and did not report, a stimulation-induced copper change [9].
  • At-risk subgroups: None established.

Regulatory status

Not addressed in labeling; no drug-specific data located.

Population evidence

Class-level only. A meta-analysis addresses serum copper elevation induced by combined oral contraceptives (estrogen-progestin, not follitropin alfa) via presumed ceruloplasmin induction [10]. That record's existence, title, journal, and DOI were confirmed via a Crossref bibliographic lookup; its full abstract could not be retrieved during this review because the publisher page and Semantic Scholar were rate-limited or blocked (HTTP 429/403) - disclosed access limitation, not treated as a fully verified supporting citation. Tier C: different drug class, and a chronic-exposure mechanism only partially analogous to an acute 8-14 day supraphysiologic estradiol pulse.

Mechanism

Plausible, class-level only: estrogen induces hepatic ceruloplasmin (the major copper-carrying protein), secondarily raising total serum copper. Whether an 8-14 day stimulation-cycle estradiol surge is long or high enough to reproduce the oral-contraceptive literature's effect size is untested for this drug.

Counter-evidence held on record

The IVF trace-element study did not identify copper elevation as a stimulation-induced finding, though it was not designed to test that question directly [9]. Theoretical only. Do not present as an established follitropin alfa effect, and do not recommend copper restriction or supplementation on this basis.

Iron

Not graded — disclosed evidence gap

See study details

No mechanism, no class-level supporting data, and no circulating claim were found for follitropin alfa and iron status in either direction.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition met: (a) no Tier B/C evidence supports even a yellow-level mechanism specific to follitropin alfa or gonadotropins raising or lowering iron status, and (b) no circulating consumer or practitioner claim alleging that FSH/gonadotropin injections deplete iron was found, despite checking two dedicated drug-nutrient-depletion resources [13, 14], neither of which lists any fertility or gonadotropin drug at all.

Search channels tried

General web search across several phrasings ("controlled ovarian stimulation ferritin iron," "serum ferritin iron gonadotropin stimulation IVF cycle change," "oocyte retrieval blood loss anemia iron"); PubMed search-listing pages; Crossref; attempted Europe PMC, OpenAlex, and Semantic Scholar API lookups, all of which returned rate-limit or access blocks during this session (see Sources access note).

Closest analog found

Chronic-estrogen literature (oral contraceptive and pregnancy studies of iron/transferrin/TIBC) reported "no significant difference" in serum iron, total iron-binding capacity, or transferrin with hormonal contraceptive use in two older studies [11, 12] - a null finding for the closest available analog, not a positive one, so it does not clear the bar for even a yellow-level class extrapolation.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk - estrogen-axis class extrapolation, weak and time-mismatched

Yellow — Low

See study details

A general estrogen-gut microbiome axis (the "estrobolome") is described for chronic estrogen-exposure states. Because follitropin alfa raises estradiol supraphysiologically for only the 8-14 days of a stimulation cycle, any microbiome effect here is a theoretical, class-level extrapolation of uncertain relevance, not a finding in stimulated patients.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Negative/null findings: No drug-specific null studies were found either, because no drug-specific study of any kind was located.
  • At-risk subgroups: None established.

Regulatory status

Not addressed in labeling; no drug- or IVF-specific microbiome study was located despite multiple search phrasings across general web search and PubMed search-listing pages.

Population evidence

None specific to follitropin alfa, gonadotropins, or IVF stimulation. Reviews of the estrogen-gut microbiome relationship describe bidirectional estrogen-microbiome interaction in the context of the menstrual cycle, menopause, and hormone therapy - chronic or cyclic time frames, not an acute supraphysiologic pulse. Tier C at best, with a substantial time-frame mismatch to this drug's actual exposure window.

Mechanism

Plausible only by analogy to chronic-estrogen states; not demonstrated for an acute gonadotropin stimulation cycle.

Counter-evidence held on record

None specific; general uncertainty from the time-frame mismatch is the operative caveat. This is the weakest-evidence entry in the dossier. It reflects analogy to a different, chronic estrogen-exposure literature, not a finding in stimulated IVF patients, and must never be used to justify a probiotic recommendation tied to this drug.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization - hemoconcentration and hyperviscosity, bounded to OHSS

Orange — Moderate

See study details

In severe OHSS, plasma volume contracts by roughly 20%, raising hematocrit into the mid-to-high 40s% - a hemoconcentration/hyperviscosity state tied to thromboembolic risk, not an improvement in oxygen-carrying capacity.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Negative/null findings: No significant blood-volume change occurred in the 25 of 30 women who did not develop severe OHSS in the same study [5].
  • At-risk subgroups: Same OHSS-prone subgroup as above; recognized thrombophilia factors further raise thromboembolic risk per the label [1].

Regulatory status

FDA label lists hemoconcentration and thromboembolic events among OHSS clinical findings and requires hematocrit monitoring; separately warns of "thromboembolic events both in association with, and separate from OHSS." [1]

Population evidence

Prospective longitudinal study, n=30 women undergoing IVF-ET superovulation with purified urinary FSH (Metrodin HP) or recombinant FSH (Gonal-F, Serono) at approximately 225 IU/day for 10-12 days; 5 developed severe OHSS. Blood volume fell approximately 20% over days 2-4 post-hCG, then rebounded approximately 30% above baseline during recovery; mean admission hematocrit was 47% (range 45-51%) in severe cases, with no significant blood-volume change in women who did not develop OHSS [5]. This cohort explicitly names Gonal-F - Tier A for follitropin alfa specifically.

Mechanism

Named: VEGF-driven capillary permeability drives intravascular fluid into the third space (peritoneal/pleural cavity), concentrating red-cell mass by plasma contraction rather than by any true increase in red-cell production. This is a hemodynamic derangement of the labeled OHSS complication (Hard Rule 2 applies: it is not an oxygen-delivery deficiency, and it is written here strictly as a mechanism clarification, not a nutrient-style finding).

Counter-evidence held on record

No source reviewed contradicts the hemoconcentration finding itself; the only interpretive question is severity classification, not direction. Elevated hematocrit here is a warning sign of intravascular volume depletion and clot risk, not evidence of improved oxygen delivery. Management is fluid/volume correction under medical supervision - never iron supplementation or erythropoiesis support.

ATP production - localized ovarian increase

Yellow — Low

See study details

The same Gonal-f exposure that increases granulosa mitochondrial respiration also increases measurable ATP production in those cells at supraphysiologic concentration - an intended, localized bioenergetic effect supporting oocyte maturation, not a systemic ATP deficit.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Negative/null findings: Effect was concentration-dependent, most robust at supraphysiologic exposure [7].
  • At-risk subgroups: None; localized ovarian effect only.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Same study as the two entries above [7]: oxygen-consumption-rate analysis showed mitochondrial ATP production increased significantly with supraphysiological FSH (P<0.01 cumulus cells, P<0.05 mural cells). Tier B, drug-specific (Gonal-f).

Mechanism

Named: FSH-receptor-driven mitochondrial biogenesis/respiratory-chain upregulation increases local ATP synthesis to meet the energetic demand of oocyte and cumulus-cell maturation.

Counter-evidence held on record

No source reviewed suggests FSH impairs ATP synthesis at clinical concentrations. Never present this as systemic "energy support." It is a localized, follicle-level finding from a single in vitro study, and it directly undercuts, rather than supports, the popular claim that fertility injections drain cellular energy production (see Fails verification).

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Fertility injections/FSH "damage mitochondria" or "deplete cellular energy," harming egg quality

    Where it comes from: General fertility-supplement and IVF-wellness content promoting CoQ10/antioxidants for "mitochondrial support" and "egg quality" during ovarian stimulation, reviewed during this audit [15]; rarely cites a drug-level source for the implied depletion mechanism.

    Why it fails: The only drug-specific mechanistic data located (Gonal-f used directly on human granulosa cells [7]) found the opposite direction: FSH increased, not decreased, mitochondrial respiration and ATP production, and produced "negligible" oxidative damage at clinically relevant concentrations. No Tier A or Tier B source shows follitropin alfa impairing mitochondrial function, depleting CoQ10, or causing net oxidative harm to the oocyte or the patient.

All references used above
  1. GONAL-f (follitropin alfa) for injection, for subcutaneous use - FDA prescribing information. — Regulatory label, NDA 020-378 (S-045/S-067/S-075), revised 2020. EMD Serono.
  2. GONAL-F - follitropin alfa kit, DailyMed label mirror. — Same underlying FDA labeling; used to confirm renal/hepatic-impairment silence, hyperkalemia ECG instruction, ATC absence, and interaction-study text.
  3. WHO Collaborating Centre for Drug Statistics Methodology - ATC/DDD Index, code G03GA05, Follitropin alfa. — Confirms ATC classification and defined daily dose (75 U, parenteral).
  4. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, Schenker JG. "Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome." Fertil Steril. 1987. PMID 2439386. — Drug used: menotropin (human menopausal gonadotropin), not follitropin alfa.Cohort excluded this drug - used as class-level mechanistic support only, not as follitropin-alfa-specific evidence.
  5. "Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox." Fertility and Sterility. — Prospective study, n=30 IVF-ET superovulation patients (5 with severe OHSS); purified urinary FSH (Metrodin HP) or recombinant FSH (Gonal-F, Serono) explicitly named in the cohort.Author/year metadata could not be confirmed via PubMed during this review (repeated bot-verification blocks); cited by title, journal, and URL only.
  6. "Hyponatremia: An Untimely Finding in Ovarian Hyper-Stimulation Syndrome." Case report, PMC8380000. — Reports serum sodium 127 mmol/L and the ">50% prevalence" figure for OHSS-associated hyponatremia; ADH-mediated mechanism.Cohort did not name the specific FSH product used - class-level only for this drug.
  7. Lin N, van Zomeren KC, Plosch T, Hofsink N, van Veen T, Li HT, Lin J, Zhou X, Groen H, Tietge UJF, Cantineau A, Schirhagl R, Hoek A. "Follicle-stimulating hormone stimulates free radical generation without inducing substantial oxidative stress in human granulosa cells." Hum Reprod Open. 2025. PMID 40066298. — In vitro study, n=38 ICSI patients' cumulus/mural granulosa cells; recombinant FSH from a GONAL-f pre-filled pen at 6/60/600 mIU/mL. Measured free radicals, oxidative damage markers, mitochondrial respiration, and ATP production.
  8. "The Impact of Minerals on Female Fertility: A Systematic Review." PMC11643854. — Used to confirm the absence of follitropin-alfa-specific copper/iron stimulation data and to source the Grossi et al. 2017 finding that magnesium/calcium remained unchanged (slight downward trend only) during IUI/IVF stimulation.
  9. "Higher Concentrations of Essential Trace Elements in Women Undergoing IVF May Be Associated with Poor Reproductive Outcomes Following Single Euploid Embryo Transfer." Cells. 2024;13(10):839. — Prospective pilot, n=51, ICSI/PGT-A/single frozen embryo transfer; measured copper, zinc, molybdenum, selenium, lithium, iron, chromium, manganese in urine, follicular fluid, and blood. Stimulation drug not specified by name.Correlates baseline/peri-retrieval trace-element levels with outcomes; does not test or report a stimulation-induced change - class-level context only.
  10. Babić Ž, Tariba B, Kovačić J, Pizent A, Varnai VM, Macan J. "Relevance of serum copper elevation induced by oral contraceptives: a meta-analysis." Contraception. 2013;87(6):790-800. DOI 10.1016/j.contraception.2012.10.006. — Drug class: combined oral contraceptives (estrogen-progestin), not follitropin alfa.Bibliographic record confirmed via Crossref; full abstract could not be retrieved during this review because the publisher page (403) and Semantic Scholar API (429) were blocked - cited for confirmed existence and topic only.
  11. Powell LW, Jacobi JM, Gaffney TJ, Adam R. "Failure of a pure progestogen contraceptive to affect serum levels of iron, transferrin, protein-bound iodine, and transaminase." 1970. PMID 5448779. — Null finding: no effect on serum iron, TIBC, or transferrin in 30 women; progestogen contraceptive, not follitropin alfa.Cohort excluded this drug - used only as the closest available null-result analog for the Iron entry.
  12. Rosenmund A, Camponovo F, Köchli HP. "The effect of hormonal contraceptives and pregnancy on iron metabolism, plasma lactoferrin levels and granulocyte count in women." 1986. PMID 3787224. — n=51 healthy women; "no significant difference" in plasma iron, TIBC, transferrin, or ferritin reported in the accessible abstract.Cohort excluded this drug - class-level null analog for the Iron entry only.
  13. U.S. Pharmacist. "Drug-Induced Nutrient Depletions: What Pharmacists Need to Know." — Reviewed for circulating drug-nutrient-depletion claims; confirmed it does not list any fertility or gonadotropin drug.
  14. Rupa Health. "10 Commonly Prescribed Medications & The Nutrients They Deplete." — Reviewed for circulating claims; confirmed it does not list any fertility or gonadotropin drug.
  15. IVF Center Hawaii. "Fertility Treatment: Vitamin D & CoQ10 Insights." — Reviewed for circulating claims; frames CoQ10/vitamin D as general fertility supplements for age-related mitochondrial decline, not as remedying a follitropin-alfa-specific depletion. Basis for the Fails Verification entry's "where the claim comes from" framing.